Revised SPCs: Lynparza (olaparib) – all strengths

SPC updated with additional indication - for the first-line maintenance treatment of homologous recombination deficiency (HRD)-positive advanced ovarian cancer in combination with bevacizumab.

electronic Medicines compendium